Stefanie Petrou Binder, MD
Newer overactive bladder agent viable alternative to antimuscarinics
Data from a recent multicenter study provide new evidence that the beta-3 adrenoceptor agonist mirabegron (Myrbetriq) appears to be a viable alternative in patients with overactive bladder who are poor responders to antimuscarinic agents or intolerant of their adverse events.
Equal pain relief across interstitial cystitis phenotypes with botulinum
Trigonal onabotulinumtoxinA (Botox) brings equal analgesic relief to patients with ulcerative and non-ulcerative forms of bladder pain syndrome/interstitial cystitis alike, according to the results of a recent study.
Investigational OAB agent efficacious, well tolerated
THVD-201 (Tolenix), a novel formulation combining tolterodine and pilocarpine, was found safe, well tolerated, and effective against overactive bladder (OAB) in a recent study.
Anterior sampling may be safe alternative for prostate biopsy
Transrectal anterior zone sampling of the prostate may be a viable alternative to transperineal template biopsies in patients with negative previous biopsies and with rising PSA or persistently elevated PSA, researchers from the United Kingdom report.
PSA screening cuts prostate cancer deaths by 32%, ERSPC data indicate
New evidence from the second-largest section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) suggests that prostate cancer screening is beneficial, particularly in the core age group of 55 to 69 years.
Study: Age is only significant predictor of nocturia
While many characteristics and conditions are associated with nocturia, patient age is the only factor that can significantly be linked with its development, Dutch researchers report.
Nocturia: Little progression at 1 year in men with BPH
In patients with symptoms suggestive of BPH, nocturia fluctuates but does not significantly progress over the course of 1-year follow-up, according to findings from a recent international study.
Lowering voltage for CT viable in stone analysis
In patients with stone disease, lowering the tube voltage set in dual-energy computed tomography by as much as 38% allowed a dose reduction without impairing stone analysis, a recent investigation showed.
Long warm ischemia time leads to kidney function loss
In patients undergoing partial nephrectomy, warm ischemia time greater than 25 minutes is associated with greater loss of kidney function, according to a recent report.
Opinion split on prescribing phosphodiesterase type-5 inhibitors for pleasure only
Physician opinion is divided almost evenly on the question of whether to prescribe phosphodiesterase type-5 inhibitors to patients for non-medical indications, a survey of Israeli doctors showed.


View Results